{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:52:20Z","timestamp":1771005140928,"version":"3.50.1"},"publisher-location":"Berlin, Heidelberg","reference-count":79,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642035029","type":"print"},{"value":"9783642035036","type":"electronic"}],"license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/978-3-642-03503-6_4","type":"book-chapter","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T10:17:12Z","timestamp":1312539432000},"page":"65-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Acid Reflux and Oesophageal Cancer"],"prefix":"10.1007","author":[{"given":"Anna","family":"Nicholson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,6]]},"reference":[{"issue":"4","key":"4_CR1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bpg.2008.03.002","volume":"22","author":"D Armstrong","year":"2008","unstructured":"Armstrong D (2008) Should patients with Barrett\u2019s oesophagus be kept under surveillance? The case for. Best Pract Res Clin Gastroenterol 22(4):721\u2013739","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"4_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.bpg.2006.04.003","volume":"20","author":"PA Atherfold","year":"2006","unstructured":"Atherfold PA, Jankowski JA (2006) Molecular biology of Barrett\u2019s cancer. Best Pract Res Clin Gastroenterol 20(5):813\u2013827","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"9255","key":"4_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539\u2013545","journal-title":"Lancet"},{"issue":"9651","key":"4_CR4","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(08)61490-7","volume":"372","author":"JA Baron","year":"2008","unstructured":"Baron JA et al (2008) Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 372(9651):1756\u20131764","journal-title":"Lancet"},{"issue":"1","key":"4_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/8816","volume":"22","author":"MT Barrett","year":"1999","unstructured":"Barrett MT et al (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22(1):106\u2013109","journal-title":"Nat Genet"},{"issue":"4","key":"4_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bpg.2007.12.005","volume":"22","author":"AS Barritt","year":"2008","unstructured":"Barritt AS, Shaheen NJ (2008) Should patients with Barrett\u2019s oesophagus be kept under surveillance? The case against. Best Pract Res Clin Gastroenterol 22(4):741\u2013750","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"4_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/00008469-200108000-00006","volume":"10","author":"R Benamouzig","year":"2001","unstructured":"Benamouzig R et al (2001) APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: design and baseline findings. Eur J Cancer Prev 10(4):327\u2013335","journal-title":"Eur J Cancer Prev"},{"issue":"2","key":"4_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S0016-5085(03)00887-4","volume":"125","author":"R Benamouzig","year":"2003","unstructured":"Benamouzig R et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125(2):328\u2013336","journal-title":"Gastroenterology"},{"key":"4_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-3-540-69297-3_22","volume":"181","author":"C Bosetti","year":"2009","unstructured":"Bosetti C, Gallus S, La Vecchia C (2009) Aspirin and cancer risk: a summary review to 2007. Recent Results Cancer Res 181:231\u2013251","journal-title":"Recent Results Cancer Res"},{"issue":"7","key":"4_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/annonc\/mdn054","volume":"19","author":"ER Brown","year":"2008","unstructured":"Brown ER et al (2008) A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 19(7):1340\u20131346","journal-title":"Ann Oncol"},{"issue":"7","key":"4_CR11","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1053\/gast.2002.33580","volume":"122","author":"CJ Buskens","year":"2002","unstructured":"Buskens CJ et al (2002) Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 122(7):1800\u20131807","journal-title":"Gastroenterology"},{"issue":"4","key":"4_CR12","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/0016-5085(90)90607-3","volume":"99","author":"AJ Cameron","year":"1990","unstructured":"Cameron AJ et al (1990) Prevalence of columnar-lined (Barrett\u2019s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 99(4):918\u2013922","journal-title":"Gastroenterology"},{"issue":"21","key":"4_CR13","doi-asserted-by":"publisher","first-page":"6988","DOI":"10.1158\/1078-0432.CCR-07-5063","volume":"14","author":"DL Chao","year":"2008","unstructured":"Chao DL et al (2008) Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett\u2019s esophagus: a long-term prospective study. Clin Cancer Res 14(21):6988\u20136995","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4_CR14","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1053\/j.gastro.2007.06.061","volume":"133","author":"NJ Clemons","year":"2007","unstructured":"Clemons NJ, McColl KE, Fitzgerald RC (2007) Nitric oxide and acid induce double-strand DNA breaks in Barrett\u2019s esophagus carcinogenesis via distinct mechanisms. Gastroenterology 133(4):1198\u20131209","journal-title":"Gastroenterology"},{"issue":"4","key":"4_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djn485","volume":"101","author":"BF Cole","year":"2009","unstructured":"Cole BF et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomised trials. J Natl Cancer Inst 101(4):256\u2013266","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/gast.2003.50008","volume":"124","author":"DA Corley","year":"2003","unstructured":"Corley DA et al (2003) Protective association of aspirin\/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124(1):47\u201356","journal-title":"Gastroenterology"},{"issue":"6917","key":"4_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860\u2013867","journal-title":"Nature"},{"key":"4_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","volume":"10","author":"Jack Cuzick","year":"2009","unstructured":"Cuzick Jack, Otto Florian, Baron John A, Brown Powel H, Burn John, Greenwald Peter, Jankowski Janusz, Vecchia Carlo La, Meyskens Frank, Senn Hans J\u00f6rg, Thun Michael (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501\u2013507","journal-title":"Lancet Oncol"},{"key":"4_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-3-540-69297-3_15","volume":"181","author":"D Das","year":"2009","unstructured":"Das D, Chilton AP, Jankowski JA (2009) Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 181:161\u2013169","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"4_CR20","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/gut.2004.051821","volume":"54","author":"J Dent","year":"2005","unstructured":"Dent J et al (2005) Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54(5):710\u2013717","journal-title":"Gut"},{"issue":"5","key":"4_CR75","first-page":"936","volume":"31","author":"HF Dvorak","year":"1986","unstructured":"Duggan SP et al (2010) An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid response gene, which regulates NF-kappaB activation and cytokine levels. Carcinogenesis 31(5): 936-945","journal-title":"Carcinogenesis"},{"issue":"26","key":"4_CR21","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","volume":"315","author":"HF Dvorak","year":"1986","unstructured":"Dvorak HF (1986) tumours: wounds that do not heal Similarities between tumour stroma generation and wound healing. N Engl J Med 315(26):1650\u20131659","journal-title":"N Engl J Med"},{"issue":"1","key":"4_CR22","first-page":"27","volume":"92","author":"GM Eisen","year":"1997","unstructured":"Eisen GM et al (1997) The relationship between gastroesophageal reflux disease and its complications with Barrett\u2019s esophagus. Am J Gastroenterol 92(1):27\u201331","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"4_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00008469-200104000-00008","volume":"10","author":"JA Eksteen","year":"2001","unstructured":"Eksteen JA et al (2001) Inflammation promotes Barrett\u2019s metaplasia and cancer: a unique role for TNFalpha. Eur J Cancer Prev 10(2):163\u2013166","journal-title":"Eur J Cancer Prev"},{"issue":"6776","key":"4_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/35006081","volume":"404","author":"EM El-Omar","year":"2000","unstructured":"El-Omar EM et al (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404(6776):398\u2013402","journal-title":"Nature"},{"issue":"3","key":"4_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/gut.2007.127878","volume":"57","author":"H El-Serag","year":"2008","unstructured":"El-Serag H (2008) Role of obesity in GORD-related disorders. Gut 57(3):281\u2013284","journal-title":"Gut"},{"issue":"2","key":"4_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/gut.2007.145581","volume":"58","author":"R Fass","year":"2009","unstructured":"Fass R, Sifrim D (2009) Management of heartburn not responding to proton pump inhibitors. Gut 58(2):295\u2013309","journal-title":"Gut"},{"issue":"22","key":"4_CR27","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/jnci\/94.22.1680","volume":"94","author":"C Figueiredo","year":"2002","unstructured":"Figueiredo C et al (2002) Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 94(22):1680\u20131687","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"4_CR28","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1046\/j.1365-2036.2001.00998.x","volume":"15","author":"LA Fischbach","year":"2001","unstructured":"Fischbach LA et al (2001) Anti-inflammatory and tissue-protectant drug effects: results from a randomised placebo-controlled trial of gastritis patients at high risk for gastric cancer. Aliment Pharmacol Ther 15(6):831\u2013841","journal-title":"Aliment Pharmacol Ther"},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/3-540-26980-0_3","volume":"166","author":"RC Fitzgerald","year":"2005","unstructured":"Fitzgerald RC (2005) Genetics and prevention of oesophageal adenocarcinoma. Recent Results Cancer Res 166:35\u201346","journal-title":"Recent Results Cancer Res"},{"issue":"3","key":"4_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/gut.51.3.316","volume":"51","author":"RC Fitzgerald","year":"2002","unstructured":"Fitzgerald RC et al (2002a) Inflammatory gradient in Barrett\u2019s oesophagus: implications for disease complications. Gut 51(3):316\u2013322","journal-title":"Gut"},{"issue":"4","key":"4_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1136\/gut.50.4.451","volume":"50","author":"RC Fitzgerald","year":"2002","unstructured":"Fitzgerald RC et al (2002b) Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50(4):451\u2013459","journal-title":"Gut"},{"issue":"8","key":"4_CR32","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1111\/j.1572-0241.2008.01946.x","volume":"103","author":"FK Friedenberg","year":"2008","unstructured":"Friedenberg FK et al (2008) The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol 103(8):2111\u20132122","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"4_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.onc.1210908","volume":"27","author":"M Fukata","year":"2008","unstructured":"Fukata M, Abreu MT (2008) Role of toll-like receptors in gastrointestinal malignancies. Oncogene 27(2):234\u2013243","journal-title":"Oncogene"},{"issue":"1","key":"4_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2036.2006.02963.x","volume":"24","author":"M Fullard","year":"2006","unstructured":"Fullard M et al (2006) Systematic review: does gastro-oesophageal reflux disease progress? Aliment Pharmacol Ther 24(1):33\u201345","journal-title":"Aliment Pharmacol Ther"},{"issue":"29","key":"4_CR35","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","volume":"25","author":"ML Harrison","year":"2007","unstructured":"Harrison ML et al (2007) Tumour necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 25(29):4542\u20134549","journal-title":"J Clin Oncol"},{"issue":"3","key":"4_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1046\/j.1442-2050.2003.00325.x","volume":"16","author":"EI Heath","year":"2003","unstructured":"Heath EI et al (2003) Chemoprevention for Barrett\u2019s esophagus trial. Design and outcome measures. Dis Esophagus 16(3):177\u2013186","journal-title":"Dis Esophagus"},{"issue":"7","key":"4_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/jnci\/djk112","volume":"99","author":"EI Heath","year":"2007","unstructured":"Heath EI et al (2007) Secondary chemoprevention of Barrett\u2019s esophagus with celecoxib: results of a randomised trial. J Natl Cancer Inst 99(7):545\u2013557","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"4_CR38","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1158\/0008-5472.CAN-08-3703","volume":"69","author":"K Hormi-Carver","year":"2009","unstructured":"Hormi-Carver K et al (2009) Unlike esophageal squamous cells, Barrett\u2019s epithelial cells resist apoptosis by activating the nuclear factor-kappa B pathway. Cancer Res 69(2):672\u2013677","journal-title":"Cancer Res"},{"issue":"3","key":"4_CR39","doi-asserted-by":"crossref","first-page":"G626","DOI":"10.1152\/ajpgi.2001.281.3.G626","volume":"281","author":"M Jaiswal","year":"2001","unstructured":"Jaiswal M, LaRusso NF, Gores GJ (2001) Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 281(3):G626\u2013G634","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"7556","key":"4_CR40","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1136\/bmj.332.7556.1512","volume":"332","author":"J Jankowski","year":"2006","unstructured":"Jankowski J, Barr H (2006) Improving surveillance for Barrett\u2019s oesophagus: AspECT and BOSS trials provide an evidence base. Bmj 332(7556):1512","journal-title":"Bmj"},{"issue":"2","key":"4_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/ncpgasthep0412","volume":"3","author":"JA Jankowski","year":"2006","unstructured":"Jankowski JA, Hawk ET (2006) A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 3(2):101\u2013111","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"4_CR42","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1158\/1055-9965.EPI-07-0710","volume":"17","author":"J Jankowski","year":"2008","unstructured":"Jankowski J, Hunt R (2008) Cyclooxygenase-2 inhibitors in colorectal cancer prevention; better the devil you know. Cancer Epidemiol Biomarkers Prev 17:1858\u20131861","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"4_CR43","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S0002-9440(10)65346-1","volume":"154","author":"JA Jankowski","year":"1999","unstructured":"Jankowski JA et al (1999) Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 154(4):965\u2013973","journal-title":"Am J Pathol"},{"issue":"9247","key":"4_CR44","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1016\/S0140-6736(00)03411-5","volume":"356","author":"JA Jankowski","year":"2000","unstructured":"Jankowski JA et al (2000) Barrett\u2019s metaplasia. Lancet 356(9247):2079\u20132085","journal-title":"Lancet"},{"issue":"2","key":"4_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71\u201396","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4_CR46","first-page":"507","volume":"29","author":"M Kerkhof","year":"2007","unstructured":"Kerkhof M et al (2007) Biomarkers for risk stratification of neoplastic progression in Barrett esophagus. Cell Oncol 29(6):507\u2013517","journal-title":"Cell Oncol"},{"issue":"4","key":"4_CR47","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1056\/NEJMoa071841","volume":"357","author":"DJ Kerr","year":"2007","unstructured":"Kerr DJ et al (2007) Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357(4):360\u2013369","journal-title":"N Engl J Med"},{"issue":"12","key":"4_CR48","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1023\/A:1018891923998","volume":"42","author":"R Kim","year":"1997","unstructured":"Kim R et al (1997) Expression of p53, PCNA, and C-erbB-2 in Barrett\u2019s metaplasia and adenocarcinoma. Dig Dis Sci 42(12):2453\u20132462","journal-title":"Dig Dis Sci"},{"issue":"8","key":"4_CR49","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/gut.2006.119206","volume":"57","author":"GH Koek","year":"2008","unstructured":"Koek GH et al (2008) Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett\u2019s oesophagus. Gut 57(8):1056\u20131064","journal-title":"Gut"},{"issue":"Suppl 1","key":"4_CR50","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/gut.2004.041517","volume":"54","author":"J Lagergren","year":"2005","unstructured":"Lagergren J (2005) Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 54(Suppl 1):i1\u2013i5","journal-title":"Gut"},{"issue":"1","key":"4_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2007.10.014","volume":"134","author":"RF Logan","year":"2008","unstructured":"Logan RF et al (2008) Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134(1):29\u201338","journal-title":"Gastroenterology"},{"issue":"19","key":"4_CR52","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1158\/1078-0432.CCR-04-0730","volume":"10","author":"S Madhusudan","year":"2004","unstructured":"Madhusudan S et al (2004) A phase II study of etanercept (Enbrel), a tumour necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 10(19):6528\u20136534","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4_CR53","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1158\/0008-5472.CAN-03-3249","volume":"64","author":"CC Maley","year":"2004","unstructured":"Maley CC et al (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett\u2019s esophagus. Cancer Res 64(10):3414\u20133427","journal-title":"Cancer Res"},{"issue":"1","key":"4_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1079\/PNS2002236","volume":"62","author":"JC Mathers","year":"2003","unstructured":"Mathers JC et al (2003) Can resistant starch and\/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study. Proc Nutr Soc 62(1):51\u201357","journal-title":"Proc Nutr Soc"},{"key":"4_CR76","doi-asserted-by":"crossref","unstructured":"Moayyedi P, Jankowski JA (2010) Does long-term aspirin prevent cancer? BMJ 341","DOI":"10.1136\/bmj.c7326"},{"issue":"3","key":"4_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/path.1847","volume":"207","author":"LM Moons","year":"2005","unstructured":"Moons LM et al (2005) Barrett\u2019s oesophagus is characterised by a predominantly humoral inflammatory response. J Pathol 207(3):269\u2013276","journal-title":"J Pathol"},{"issue":"1","key":"4_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1572-0241.1999.00768.x","volume":"94","author":"S Nandurkar","year":"1999","unstructured":"Nandurkar S, Talley NJ (1999) Barrett\u2019s esophagus: the long and the short of it. Am J Gastroenterol 94(1):30\u201340","journal-title":"Am J Gastroenterol"},{"issue":"23","key":"4_CR77","first-page":"5824","volume":"16","author":"S Nandurkar","year":"1999","unstructured":"Nguyen GH et al (2010) Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res 16(23):5824\u20135834","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4_CR57","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/j.1572-0241.2005.41338.x","volume":"100","author":"JM O\u2019Riordan","year":"2005","unstructured":"O\u2019Riordan JM et al (2005) Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 100(6):1257\u20131264","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4_CR58","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/archsurg.142.6.554","volume":"142","author":"DS Oh","year":"2007","unstructured":"Oh DS et al (2007) Reduction of interleukin 8 gene expression in reflux esophagitis and Barrett\u2019s esophagus with antireflux surgery. Arch Surg 142(6):554\u2013559 (discussion 559\u2013560)","journal-title":"Arch Surg"},{"issue":"1","key":"4_CR59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3816\/CCC.2003.n.013","volume":"3","author":"S Pendlebury","year":"2003","unstructured":"Pendlebury S et al (2003) A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer 3(1):58\u201360","journal-title":"Clin Colorectal Cancer"},{"issue":"9759","key":"4_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","volume":"377","author":"PM Rothwell","year":"2011","unstructured":"Rothwell PM et al (2011) Effect of daily Aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31\u201341","journal-title":"Lancet"},{"issue":"5","key":"4_CR79","first-page":"2177","volume":"107","author":"V Savarino","year":"2004","unstructured":"Saadi A et al (2009) Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. PNAS 107(5):2177\u20132182","journal-title":"PNAS"},{"issue":"Suppl 1","key":"4_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000076371","volume":"69","author":"V Savarino","year":"2004","unstructured":"Savarino V, Dulbecco P (2004) Optimizing symptom relief and preventing complications in adults with gastro-oesophageal reflux disease. Digestion 69(Suppl 1):9\u201316","journal-title":"Digestion"},{"issue":"6","key":"4_CR61","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2005.03.032","volume":"128","author":"NJ Shaheen","year":"2005","unstructured":"Shaheen NJ (2005) Advances in Barrett\u2019s esophagus and esophageal adenocarcinoma. Gastroenterology 128(6):1554\u20131566","journal-title":"Gastroenterology"},{"issue":"9666","key":"4_CR62","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(09)60487-6","volume":"373","author":"NJ Shaheen","year":"2009","unstructured":"Shaheen NJ, Richter JE (2009) Barrett\u2019s oesophagus. Lancet 373(9666):850\u2013861","journal-title":"Lancet"},{"issue":"5","key":"4_CR63","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1586\/17474124.2.5.653","volume":"2","author":"I Tischoff","year":"2008","unstructured":"Tischoff I, Tannapfel A (2008) Barrett\u2019s esophagus: can biomarkers predict progression to malignancy? Expert Rev Gastroenterol Hepatol 2(5):653\u2013663","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"39","key":"4_CR64","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1038\/sj.onc.1205731","volume":"21","author":"C Tselepis","year":"2002","unstructured":"Tselepis C et al (2002) Tumour necrosis factor-alpha in Barrett\u2019s oesophagus: a potential novel mechanism of action. Oncogene 21(39):6071\u20136081","journal-title":"Oncogene"},{"issue":"12","key":"4_CR65","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S1470-2045(05)70431-9","volume":"6","author":"TL Vaughan","year":"2005","unstructured":"Vaughan TL et al (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett\u2019s oesophagus: a prospective study. Lancet Oncol 6(12):945\u2013952","journal-title":"Lancet Oncol"},{"issue":"4","key":"4_CR66","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/0008-5472.CAN-07-5021","volume":"68","author":"Y Wang","year":"2008","unstructured":"Wang Y et al (2008) Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res 68(4):1136\u20131143","journal-title":"Cancer Res"},{"issue":"5","key":"4_CR67","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1111\/j.1572-0241.2001.03851.x","volume":"96","author":"AP Weston","year":"2001","unstructured":"Weston AP et al (2001) p53 protein overexpression in low grade dysplasia (LGD) in Barrett\u2019s esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 96(5):1355\u20131362","journal-title":"Am J Gastroenterol"},{"issue":"14","key":"4_CR68","first-page":"2929","volume":"58","author":"KT Wilson","year":"1998","unstructured":"Wilson KT et al (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett\u2019s esophagus and associated adenocarcinomas. Cancer Res 58(14):2929\u20132934","journal-title":"Cancer Res"},{"issue":"13","key":"4_CR69","first-page":"2619","volume":"57","author":"DJ Wong","year":"1997","unstructured":"Wong DJ et al (1997) p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 57(13):2619\u20132622","journal-title":"Cancer Res"},{"issue":"22","key":"4_CR70","first-page":"8284","volume":"61","author":"DJ Wong","year":"2001","unstructured":"Wong DJ et al (2001) p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett\u2019s metaplastic epithelium. Cancer Res 61(22):8284\u20138289","journal-title":"Cancer Res"},{"issue":"21","key":"4_CR71","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1073\/pnas.0502031102","volume":"102","author":"NA Wong","year":"2005","unstructured":"Wong NA et al (2005) CDX1 is an important molecular mediator of Barrett\u2019s metaplasia. Proc Natl Acad Sci USA 102(21):7565\u20137570","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"4_CR72","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1023\/A:1018828207371","volume":"42","author":"M Younes","year":"1997","unstructured":"Younes M et al (1997) p53 Protein accumulation is a specific marker of malignant potential in Barrett\u2019s metaplasia. Dig Dis Sci 42(4):697\u2013701","journal-title":"Dig Dis Sci"},{"issue":"4","key":"4_CR73","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1053\/hp.2000.6715","volume":"31","author":"M Younes","year":"2000","unstructured":"Younes M et al (2000) Decreased expression of Fas (CD95\/APO1) associated with goblet cell metaplasia in Barrett\u2019s esophagus. Hum Pathol 31(4):434\u2013438","journal-title":"Hum Pathol"},{"issue":"2","key":"4_CR74","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.canlet.2008.07.006","volume":"275","author":"HY Zhang","year":"2009","unstructured":"Zhang HY, Spechler SJ, Souza RF (2009) Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett 275(2):170\u2013177","journal-title":"Cancer Lett"}],"container-title":["Recent Results in Cancer Research","Inflammation and Gastrointestinal Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-03503-6_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T14:44:45Z","timestamp":1674744285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-03503-6_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"ISBN":["9783642035029","9783642035036"],"references-count":79,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-03503-6_4","relation":{},"ISSN":["0080-0015"],"issn-type":[{"value":"0080-0015","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]},"assertion":[{"value":"6 August 2011","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}